405. so you want to publish your research in the journal of thrombosis and haemostasis 411. safety and efficacy of BAY 94-9027 a prolonged half life factor VIII 420. Bleeding risk of terminally i…
1557. Early postoperative bridging anticoagulation after mechanical heart valve replacement a systematic review and meta analysis 1568. Hypercoagulabiluty and the risk of myocardial infraction a…
1743. New paradigms in sepsis from prevention to protection of failing microcirculation 1757. Circulatory support devices fundamental aspects and clinical management of bleeding and thrombosis 17…
6. ADAMTS-13 and von willebrand factors 19. Associations of activated coagulation factor VII and factor VIIa antithrombin levels with genome wide polymorphisms and cardiovascular 31. Natural anti…
1325. To measure or not to measure direct oral anticoagulants before surgery or invasive procedures 1328. Early career profesionals the mission of a task force 1330. Tailoring hemostatic therapie…
1495. Unique challenges and experiences of trainees from reach the world countries 1507. A diagnostic approach to mild bleeding disorders 1517. Neutralizing autoantibody against factor XIII A sub…
2300. A large case series on surgical outcomes in congenital factor XIII deficiency patients 2306. Elevated preoperative von willebrand factor is associated with peroperiative thrombosis in infant…
1121. Gene therapy for immune tolerance induction in hemophilia with inhibitors 1135. The design and synthesis of new synthetic low molecular weight heparins 1146. Contemporary antiplatelet trea…
873. Vasa vasorum and atherosclerosis 880. Circulating P-selection and the risk of reccurent venous thromboembolisms 884. Characterisation of five factor XI mutations 890. Calcium-binding sites…
917. CXCL4 in atherosclerosis : Possible roles in monocyte arrest and macrophage foam cell formation 919. Vascular remodelling processes cells, signals and their integration 922. Platelet intera…